iShares Fallen Angels USD Bond ETF (NASDAQ: FALN)

Ultime notizie per iShares Fallen Angels USD Bond ETF (NASDAQ:FALN)

iShares Fallen Angels USD Bond ETF

The fund seeks to track the investment results of the Bloomberg Barclays US High Yield Fallen Angel 3% Capped Index (the Underlying Index), which is designed to reflect the performance of U.S. dollar denominated, high yield. the Fund will invest at least 90% of its assets in fixed income securities of the types included in the Underlying Index that BFA believes will help the Fund track the Underlying Index. The Fund will invest no more than 10% of its assets in futures, options and swaps contracts that BFA believes will help the Fund track the Underlying Index as well as in fixed income securities other than the types included in the Underlying Index

Blackrock Cash Funds: Treasury, Sl Agency Shares

Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) stock is trading higher Tuesday. The movement appears to be driven by <a href="https://www.benzinga.com/analyst-stock-ratings">positive analyst coverage</a>.
What Happened: Morgan Stanley analyst Sanjit Singh assumed Snowflake with an Overweight rating on Tuesday and set a price target of $262, citing improvement in secular growth trends.
The analyst sees 20% upside from current levels. Snowflake shares are already up about 45% year-to-date.
Here&#8217;s a look at other analyst changes in recent weeks:
<ul class="wp-block-list">
<li>CICC initiated coverage on Snowflake with an Outperform rating and announced a price target of $225.</li>
<li>Wells Fargo analyst Michael Turrin maintained an Overweight rating on Snowflake and raised the price target from $225 to $250.</li>
<li>Oppenheimer analyst Ittai Kidron maintained an Outperform rating on Snowflake and raised the price target from $225 to $250.</li>
<li>Needham analyst Mike Cikos reiterated a Buy rating on Snowflake and maintained a price target of $230.</li>
</ul>
<h3 class="wp-block-heading">How To Buy SNOW Stock</h3>
By now you're likely curious about how to participate in the market for Snowflake &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Related Link: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080056/bigbear-ai-bbai-stock-soars-21-whats-going-on">BigBear.ai (BBAI) Stock Soars 21%: What&#8217;s Going On?</a>
SNOW Price Action: At the time of publication, Snowflake stock was up 5.01% at $224.44, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiK2vKazYqOAxVCk4kEHZD1I70QFnoECB0QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock

News

Price Target

Initiation

Movers

SNOW

Snowflake Stock Is Rising Tuesday: What's Going On?

Trading Ideas

FTRK

Fast Track Group Shares Resumed Trade, Then Again Halted On Circuit Breaker To The Downside, Stock Now Down -35.5%

<a href="https://x.com/AGLizMurrill/status/1937585255646642652" title="https://x.com/AGLizMurrill/status/1937585255646642652">https://x.com/AGLizMurrill/status/1937585255646642652</a>

Legal

Attorney General Liz Murrill Posts On X "Today, I've filed 3 separate lawsuits against CVS for unfair, deceptive, and unlawful practices that have harmed Louisiana patients, independent pharmacies, and the public at large. The State is seeking both injunctive relief and restitution."

Fast Track Group Shares Halted On Circuit Breaker

Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) shares are trading lower as oil prices fall Tuesday amid Iran-Israel <a href="https://www.benzinga.com/news/25/06/46079549/tech-stocks-eye-record-highs-crude-drops-to-64-on-iran-israel-truce-whats-driving-markets-tuesday">ceasefire efforts</a>.
The Details: According to <a href="https://www.axios.com/2025/06/24/trump-iran-israel-ceasefire-victory">Axios</a>, Iran and Israel have agreed to a ceasefire after 12 days of fighting. The deal was reportedly brokered by President Donald Trump, with support from Qatar.
Trump congratulated both countries on the ceasefire when he announced the agreement late Monday via Truth Social.
&#8220;CONGRATULATIONS TO EVERYONE! It has been fully agreed by and between Israel and Iran that there will be a Complete and Total CEASEFIRE,&#8221; Trump wrote in the <a href="https://truthsocial.com/@realDonaldTrump/posts/114734934153569653">post</a>. 
The agreement caused oil prices to fall with U.S. crude dropping close to 5.5% and Brent crude, the international benchmark, falling nearly 6%. Oil prices had gone up near the start of the conflict due to concerns about supply disruptions in the Middle East. Now that tensions are easing, traders expect oil to keep flowing, which is bringing prices down.
Lower oil prices usually lead to lower profits for oil and gas companies. That appears to be why energy stocks like Occidental are falling on Tuesday.
Trump also said China can continue buying oil from Iran. The announcement added even more pressure to oil prices as it means more supply could stay on the global market. With both the ceasefire and Trump's statement signaling steady oil availability, investors appear to be selling energy stocks across the board.
See Also: <a href="https://www.benzinga.com/news/25/06/46078773/crude-oil-falls-sharply-us-current-account-deficit-widens-in-q1">Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1</a>
OXY Price Action: At the time of writing, Occidental shares were down 3.59% at $42.37, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiYsZGnx4qOAxVphIkEHZUMKCcQFnoECBsQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

Global

Occidental Petroleum Stock Is Slipping Tuesday: What's Going On?

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is up 5% over the past 24 hours but keeps hovering around <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">a make-or-break level</a> a prominent analyst warns.
What Happened: In a recent <a href="https://x.com/Kev_Capital_TA/status/1937534740208251297">podcast</a> update, analyst Kevin pointed out the confluence of critical indicators at the $0.16 zone, including the weekly 200 Simple Moving Average (SMA), weekly 200 EMA, and the macro 0.382 Fibonacci retracement.
 "This is a very important level," he emphasized, noting it has consistently acted as a launchpad during the current bull cycle.
Kevin also cited weekly RSI resilience: in every significant correction during this cycle, the RSI has stayed above 38, keeping the broader uptrend intact.
Kevin's technical approach has been methodical. 
His team took profits in late 2024 at euphoric RSI peaks, then accurately re-entered DOGE at $0.14–$0.15 in April 2025, exiting near $0.25–$0.26. 
Now, he's back in a swing long from current levels, separate from his long-term DOGE holdings acquired at $0.06.
"We've defended this support level before," he said. "Now's the time to be patient, not fearful."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45948722/dogecoin-flashes-multiple-buy-signals-is-a-rebound-on-the-horizon">Dogecoin Flashes Multiple Buy Signals – Is A Rebound On The Horizon?</a>
What's Next: Dogecoin faces significant resistance ahead. 
Kevin notes DOGE is still trading below all major daily moving averages, which remain elevated. Reclaiming $0.19 is crucial for a return to the $0.19–$0.26 range. 
Dogecoin's next move is tightly linked to Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) direction. Kevin emphasized, "BTC runs the show doge will follow Bitcoin at the end of the day."
He views Bitcoin's recent false breakdown and bounce from a symmetrical triangle as bullish. 
For confirmation, BTC needs to break $106,800 and retake the 4-hour 200 SMA. 
If BTC rallies, Kevin expects Dogecoin to follow but warns that falling below weekly RSI 38 could break the $0.143–$0.127 range and trigger a bearish shift.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46070857/bitcoin-ethereum-xrp-dogecoin-consolidate-after-israel-iran-ceasefire-rally">Bitcoin, Ethereum, XRP, Dogecoin Consolidate After Israel-Iran Ceasefire Rally</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

Dogecoin Up 5% But Doubts Remain: What's Going On?

Bank of America Securities analysts conducted two global surveys between April 15–25 and June 3–13, gathering over 9,000 responses from travelers across the U.S., Mexico, Canada, the UK, Europe, and Japan to monitor shifting cross-border travel expectations <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noreferrer noopener">in light of ongoing macro volatility</a>.
The data indicates a rising number of international travelers plan to alter their travel plans over the coming year—though it&#8217;s acknowledged that stated intentions don&#8217;t always result in action.
In April, 44% of respondents said they would modify their cross-border travel within 12 months; this rose to 47% in June.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45925124/ripple-ceo-projects-xrp-could-handle-14-of-swifts-cross-border-payment-volume-within-five-years" target="_blank" rel="noreferrer noopener">Ripple CEO Projects XRP Could Handle 14% Of SWIFT&#8217;s Cross-Border Payment Volume Within Five Years</a>
Analysts noted that 89% of those planning to adjust travel in April pointed to concerns about government policies, such as tariffs or immigration. While travelers often cite geopolitical concerns like tariffs and immigration as their main reasons, there was a noticeable increase in price sensitivity, with 14% of June respondents pointing to cost, up from just 4% in April.
The analysts note this shift could potentially affect cross-border volumes for Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>).
Specifically, when travelers opt to cancel trips altogether or substitute domestic travel for international plans—estimated at around 10% of total respondents—this could serve as a headwind for both companies&#8217; high-yielding cross-border segments.
However, if travelers merely shift to a different international destination, the impact would likely be neutral.
Despite these signals, neither Visa nor Mastercard has flagged material cross-border weakness in their recent intra-quarter updates.
Visa maintains its fiscal second-half outlook at around 12% cross-border volume growth, consistent with March and April averages, while Mastercard continues to expect stable overall trends.
Given that a sizable portion of Visa&#8217;s and Mastercard&#8217;s international revenues are tied to cross-border travel—about 60–65%, mostly leisure-driven—BofA Securities analysts caution that any sustained softening in global travel demand could pressure growth in this category.
That&#8217;s especially true for U.S. inbound routes, which tend to be among the highest-yielding for both networks.
Visa and Mastercard remain geographically diverse, but potential pullbacks in these travel corridors, even if modest, could influence revenue trajectories in the quarters ahead, BofA Securities adds.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/travel/25/06/46045416/us-issues-worldwide-caution-after-strikes-on-irans-nuclear-sites-state-department-warns-of-airspace-closures-travel-chaos-and-rising-threats-to-americans-abroad" target="_blank" rel="noreferrer noopener">US Issues Worldwide Caution After Strikes On Iran&#8217;s Nuclear Sites: State Department Warns Of Airspace Closures, Travel Chaos And Rising Threats To Americans Abroad</a></li>
</ul>
Photo: Song_about_summer on Shutterstock.com

Equities

Travel

Markets

Analyst Ratings

General

Visa, Mastercard Exposed As More Travelers Cut Back On Overseas Plans

When your cell phone suddenly freezes on your way to grab your morning coffee, it may not be just a technical glitch, but the warning sign of the <a href="https://www.benzinga.com/topic/cyber-security">cyber thievery of the new age</a>. 
The CrowdStrike 2025 Global Threat Report found that: 
<ul class="wp-block-list">
<li>Vishing (short for &#8220;voice phishing&#8221;) attacks have increased 442%</li>
<li>Close to 80% of intrusions no longer sneak in with any malware, and </li>
<li>China-associated hackers are upping their game with a 150% jump in activity.</li>
</ul>
For individual investors who want to ride this cyber mayhem, <a href="https://www.benzinga.com/etfs">cybersecurity ETFs</a> provide a useful and effective means to tap into the digital defense boom.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/06/46080190/quantum-volatility-tradrs-new-etfs-qubx-rgtu-are-built-for-it-says-matt-markiewicz">Quantum Volatility? Tradr&#8217;s New ETFs QUBX, RGTU Are Built for It, Says Matt Markiewicz</a>
<h3 class="wp-block-heading">Why Cybersecurity, Why Now?</h3>
Hackers are getting quicker and cleverer, cracking networks in 51 seconds or less, frequently without malware. Instead, they use AI-powered phishing emails, take advantage of misconfigured clouds, and steal passwords. It&#8217;s digital jiu-jitsu, and businesses are scrambling to protect themselves.
This explosion of advanced attacks has translated into a multi-billion-dollar cybersecurity boom, and investors are sitting up and taking notice. 
<h3 class="wp-block-heading">The ETFs That Let You Invest In Digital Defense</h3>
If selecting individual <a href="https://www.benzinga.com/topic/cybersecurity">cybersecurity stocks</a> seems intimidating, these ETFs provide a diversified method to ride the wave:
First Trust Nasdaq Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>)
<ul class="wp-block-list">
<li>Assets under management: ~$10 billion</li>
<li>Top holdings: Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), Cisco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), CrowdStrike (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</li>
<li>Expense ratio: 0.59%</li>
<li>CIBR is the biggest and most liquid cybersecurity ETF on the market. It&#8217;s based on the Nasdaq CTA Cybersecurity Index and provides exposure to pure-play cyber companies as well as larger tech giants with large, healthy security segments. It&#8217;s an excellent choice for investors looking for liquidity and a diversified, weighted basket of companies that are protecting the frontlines.</li>
</ul>
Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>)
<ul class="wp-block-list">
<li>Assets under management: ~$2.27 billion</li>
<li>Top holdings: Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Palo Alto Networks, Cisco, Crowdstrike, Fortinet, Cloudflare&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>)</li>
<li>Expense ratio: 0.60%</li>
<li>HACK led the way in the space and has a slightly different methodology, it follows the ISE Cyber Security Select Index focused on revenue exposure to cybersecurity. That is to say, it frequently includes boutique players in consulting, military-grade defense, and forensic analysis. If you want more &#8220;boots-on-the-ground&#8221; exposure, HACK delivers that tactical taste.</li>
</ul>
Global X Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUG#NASDAQ">BUG</a>)
<ul class="wp-block-list">
<li>Assets under management: ~$1.14 billion</li>
<li>Leading holdings: CrowdStrike, Palo Alto Networks, Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), Fortinet, Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)</li>
<li>Expense ratio: 0.51%</li>
<li>BUG emphasizes high-growth, next-generation players and plays more towards firms focused on endpoint security, cloud-native defenses, and AI-driven threat detection. It&#8217;s slightly more volatile, but for those with a higher-risk appetite, BUG connects to the more innovative edge of the space.</li>
</ul>
<h2 class="wp-block-heading">Why It&#8217;s Not Too Late</h2>
While these ETFs have become increasingly popular, analysts suggest the cybersecurity trade isn&#8217;t yet crowded. Why? Because the threats are expanding at record pace. 
A June <a href="https://www.fortunebusinessinsights.com/industry-reports/cyber-security-market-101165">report </a>by Fortune Business Insights projects the global cybersecurity market size to grow from an estimated $193.73 billion in 2024 to $562.72 billion by 2032, realizing a CAGR of 14.3% during the period.
With data emerging as the most valuable currency and threats more sophisticated, cybersecurity is becoming one of the most defensive trades in your portfolio.
Cyber ETFs enable individual investors to ride this megatrend without the hassle of stock-picking. If you&#8217;re a conservative investor seeking stability or a tech-loving trader seeking growth, chances are there&#8217;s a cybersecurity ETF out there that&#8217;s your style.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/46078207/blackrock-launch-ishares-texn-etf-texas-based-stocks">BlackRock Debuts iShares TEXN ETF For Retail Investors Eyeing Texas-Based Stocks</a></li>
</ul>
Image: Shutterstock

Sector ETFs

ETFs

AVGO

CIBR

CRWD

CSCO

FTNT

HACK

OKTA

PANW

3 Cybersecurity ETFs To Gain Ground As Threats Go Malware-Free, China Gets Bolder

A well-known crypto analyst suggests that a major shift in Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) market dominance could soon pave the way for a significant <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">rally in altcoins</a>.
Crypto trader Rekt Capital <a href="https://x.com/rektcapital/status/1936812932568097053">told</a> his 549,600 followers on social media platform X that Bitcoin dominance, a metric tracking Bitcoin's share of the total cryptocurrency market, is approaching historically high levels that could signal a coming reversal.
According to him, this change could create the conditions for altcoins to outperform Bitcoin.
Rekt Capital pointed to the 71% Bitcoin dominance level as a key historical marker. 
"If past trends hold, a broad altcoin rally could begin when Bitcoin dominance rejects from around the 71% level," he said.
Bitcoin dominance, often abbreviated as BTC.D, reflects the percentage of the crypto market's total value held by Bitcoin. 
When this figure declines, it typically indicates that altcoins are gaining ground relative to Bitcoin.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46077689/polymarket-reportedly-looking-to-raise-200-million-at-1b-valuation">Polymarket Reportedly Looking To Raise $200 Million At $1B Valuation</a>
The analyst emphasized that the exact reversal point may not be precisely 71%, but somewhere in that vicinity. 
"It's not essential whether Bitcoin dominance tops at 71%, 69%, or 67%, the larger uptrend has mostly played out," he noted, suggesting that the market is already nearing a potential turning point.
Rekt Capital also clarified that altcoins are unlikely to lose their value entirely as Bitcoin dominance peaks. 
Instead, he expects altcoins to experience noticeable corrections similar to those seen in February 2025, when Bitcoin dominance climbed from 58% to 64%.
As of now, Bitcoin dominance stands at 65.3%, according to the analyst's tracking.
Read Next: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46075963/wealthy-investors-want-crypto-advice-but-doubt-their-advisors-experience-report">Wealthy Investors Want Crypto Advice But Doubt Their Advisors&#8217; Experience: Report</a>

Bitcoin Dominance Tops 65% But 'Altcoin Season' Is Close, Trader Says

Investors with a lot of money to spend have taken a bullish stance on CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRWV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for CoreWeave.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $217,533, and 3 are calls, for a total amount of $321,270.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $212.5 for CoreWeave over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for CoreWeave's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CoreWeave's whale trades within a strike price range from $125.0 to $212.5 in the last 30 days. 
<h3>CoreWeave Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750791925_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.5</td>
<td>$12.45</td>
<td>$12.5</td>
<td>$195.00</td>
<td>$189.5K</td>
<td>1.0K</td>
<td>311</td>
</tr>
<tr>
<td>CRWV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.2</td>
<td>$170.00</td>
<td>$98.3K</td>
<td>2.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CRWV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/03/25</td>
<td>$14.15</td>
<td>$13.45</td>
<td>$13.55</td>
<td>$175.00</td>
<td>$71.7K</td>
<td>189</td>
<td>468</td>
</tr>
<tr>
<td>CRWV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$13.8</td>
<td>$13.4</td>
<td>$13.53</td>
<td>$175.00</td>
<td>$36.5K</td>
<td>189</td>
<td>814</td>
</tr>
<tr>
<td>CRWV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$19.6</td>
<td>$19.1</td>
<td>$19.6</td>
<td>$170.00</td>
<td>$33.3K</td>
<td>1.3K</td>
<td>408</td>
</tr>
</tbody>
</table>

<h3>About CoreWeave</h3>
CoreWeave Inc is a modern cloud infrastructure technology company that offers the CoreWeave Cloud Platform which consists of proprietary software and cloud services that deliver the automation and efficiency needed to manage complex AI infrastructure at scale. Its platform supports the development and use of ground-breaking models and the delivery of the next generation of AI applications that are changing the way of living and working across the globe.
Following our analysis of the options activities associated with CoreWeave, we pivot to a closer look at the company's own performance.
<h3>Where Is CoreWeave Standing Right Now?</h3>
<ul>
<li>With a volume of 15,413,065, the price of CRWV is up 0.07% at $173.8. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 51 days.</li>
</ul>
<h3>What The Experts Say On CoreWeave</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $107.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Underperform rating for CoreWeave, targeting a price of $36. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $185. 
&#x2A; In a cautious move, an analyst from Barclays downgraded its rating to Equal-Weight, setting a price target of $100. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CoreWeave options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

CRWV

Decoding CoreWeave's Options Activity: What's the Big Picture?

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) will release its quarterly earnings report on Wednesday, 2025-06-25. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Novagold Resources to report an earnings per share (EPS) of $-0.06.
Novagold Resources bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 2.01% drop in the share price on the subsequent day.
Here's a look at Novagold Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.03</td>
<td></td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-13.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Novagold Resources's Stock</h3>
Shares of Novagold Resources were trading at $4.08 as of June 23. Over the last 52-week period, shares are up 15.34%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NG/earnings">To track all earnings releases for Novagold Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What's Next: Novagold Resources's Earnings Preview

Across the recent three months, 33 analysts have shared their insights on Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">12</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $191.18, along with a high estimate of $240.00 and a low estimate of $159.00. This current average has decreased by 6.27% from the previous average price target of $203.97. 
<img src="https://www.benzinga.com/files/images/story/2025/1750791672_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Alphabet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$203.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$189.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$178.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$189.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$192.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$178.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$178.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$229.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$167.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alphabet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Alphabet compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Alphabet's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alphabet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alphabet analyst ratings.</a>
<h2>Get to Know Alphabet Better</h2>
Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.
<h3>A Deep Dive into Alphabet's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Alphabet's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 12.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Alphabet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Alphabet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 7.46%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alphabet's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GOOGL

Forecasting The Future: 33 Analyst Projections For Alphabet

Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-06-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Daktronics will report an earnings per share (EPS) of $0.29.
Investors in Daktronics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.08 in the last quarter, leading to a 4.72% increase in the share price on the following day.
Here's a look at Daktronics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.20</td>
<td>0.28</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.01</td>
<td>0.27</td>
<td>0.36</td>
<td>0.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750791669_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Daktronics were trading at $14.87 as of June 23. Over the last 52-week period, shares are up 14.55%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DAKT/earnings">To track all earnings releases for Daktronics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAKT

Daktronics's Earnings: A Preview

Providing a diverse range of perspectives from bullish to bearish, 25 analysts have published ratings on Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $93.52, with a high estimate of $111.00 and a low estimate of $70.00. Witnessing a positive shift, the current average has risen by 8.95% from the previous average price target of $85.84.
<img src="https://www.benzinga.com/files/images/story/2025/1750791663_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Dollar Tree's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$96.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$79.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$85.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dollar Tree. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Dollar Tree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dollar Tree's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dollar Tree analyst ratings.</a>
<h2>Delving into Dollar Tree's Background</h2>
Dollar Tree operates discount stores across the United States and Canada, with over 8,800 shops under its namesake banner. About 50% of Dollar Tree's sales in fiscal 2024 were consumables (including food, health and beauty, and cleaning products), around 45% variety items (including toys and homewares), and 5% seasonal items. Dollar Tree sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. The retailer has agreed to sell Family Dollar (with about 7,000 stores) to private equity investors for $1 billion.
<h3>Key Indicators: Dollar Tree's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Dollar Tree showcased positive performance, achieving a revenue growth rate of 11.29% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Dollar Tree's net margin is impressive, surpassing industry averages. With a net margin of 7.4%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Dollar Tree's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.86%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.03, Dollar Tree faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DLTR

Forecasting The Future: 25 Analyst Projections For Dollar Tree

Across the recent three months, 8 analysts have shared their insights on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $310.62, along with a high estimate of $330.00 and a low estimate of $280.00. This current average has increased by 0.9% from the previous average price target of $307.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1750791652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Neutral</td>
<td>$288.00</td>
<td>-</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$324.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$319.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$330.00</td>
<td>$328.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amgen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Amgen's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Amgen analyst ratings.</a>
<h2>Get to Know Amgen Better</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Breaking Down Amgen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Amgen showcased positive performance, achieving a revenue growth rate of 9.43% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 28.63%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Amgen's ROA stands out, surpassing industry averages. With an impressive ROA of 1.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 9.24, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

Where Amgen Stands With Analysts

Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-06-25. Here's what investors need to know before the announcement.
Analysts estimate that Paychex will report an earnings per share (EPS) of $1.19. 
Anticipation surrounds Paychex's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 1.09% increase in the share price the next day.
Here's a look at Paychex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.48</td>
<td>1.13</td>
<td>1.14</td>
<td>1.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.49</td>
<td>1.14</td>
<td>1.16</td>
<td>1.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750791645_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Paychex were trading at $151.25 as of June 23. Over the last 52-week period, shares are up 29.37%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Opinions on Paychex</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Paychex.
Analysts have given Paychex a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target is $154.0, indicating a potential 1.82% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Paycom Software, Paylocity Holding and Dayforce, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Paycom Software, with an average 1-year price target of $251.2, suggesting a potential 66.08% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Paylocity Holding, with an average 1-year price target of $230.07, suggesting a potential 52.11% upside.</li>
<li>Analysts currently favor an Buy trajectory for Dayforce, with an average 1-year price target of $68.0, suggesting a potential 55.04% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Paycom Software, Paylocity Holding and Dayforce are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paychex</td>
<td>Neutral</td>
<td>4.84%</td>
<td>$1.12B</td>
<td>12.91%</td>
</tr>
<tr>
<td>Paycom Software</td>
<td>Neutral</td>
<td>6.12%</td>
<td>$445.90M</td>
<td>8.47%</td>
</tr>
<tr>
<td>Paylocity Holding</td>
<td>Outperform</td>
<td>13.27%</td>
<td>$324.69M</td>
<td>7.68%</td>
</tr>
<tr>
<td>Dayforce</td>
<td>Buy</td>
<td>11.66%</td>
<td>$242.80M</td>
<td>0.58%</td>
</tr>
</tbody>
</table>

Key Takeaway:
In terms of consensus rating, Paychex is in the middle compared to its peers. Paychex has the highest revenue growth among its peers. Paychex also leads in gross profit. However, Paychex has the lowest return on equity compared to its peers.
<h3>All You Need to Know About Paychex</h3>
Paychex is a technology company providing human capital management solutions, enabling clients to better implement payroll, talent, time, tax, and benefits administration. It has a diverse set of product offerings addressing client needs. Aside from its traditional cloud-based payroll and HCM software offering, which accounts for close to half of total revenue, the company provides outsourcing options. Paychex's administrative service organization and professional employer organization accounts generate over 40% of sales. The balance of revenue is generated through retirement services, insurance solutions, and other products. In fiscal 2024, the company had 745,000 clients and over 2.3 million worksite employees across its ASO and PEO.
<h3>Paychex's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Paychex's remarkable performance in 3 months is evident. As of 28 February, 2025, the company achieved an impressive revenue growth rate of 4.84%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Paychex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 34.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Paychex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.91% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Paychex's ROA stands out, surpassing industry averages. With an impressive ROA of 4.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Paychex's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/PAYX/earnings">To track all earnings releases for Paychex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYX

A Peek at Paychex's Future Earnings

Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) has been analyzed by 16 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $163.69, with a high estimate of $210.00 and a low estimate of $135.00. Marking an increase of 10.37%, the current average surpasses the previous average price target of $148.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1750791643_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Electronic Arts among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Handler</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Omar Dessouky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$167.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$148.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Karnovsky</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Omar Dessouky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Karnovsky</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Electronic Arts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Electronic Arts compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Electronic Arts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Electronic Arts's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Electronic Arts analyst ratings.</a>
<h2>All You Need to Know About Electronic Arts</h2>
Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.
<h3>Electronic Arts: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Electronic Arts's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.52% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Electronic Arts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Electronic Arts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.97%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Electronic Arts adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Electronic Arts: 16 Analysts Share Their Views

FactSet Research Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) short percent of float has risen 8.88% since its last report. The company recently reported that it has 1.56 million shares sold short, which is 4.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>FactSet Research Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750791630_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for FactSet Research Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing FactSet Research Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, FactSet Research Systems's peer group average for short interest as a percentage of float is 6.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About FactSet Research Systems?

In the current session, the stock is trading at $8.20, after a 2.50% increase. Over the past month, Banco Santander Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) stock increased by 2.80%, and in the past year, by 78.73%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1750791630_0_0.png" alt="Past Year Chart" />

<h3>How Does Banco Santander P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Banco Santander has a lower P/E than the aggregate P/E of 12.7 of the Banks industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750791630_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Banco Santander Inc's Price Over Earnings

8 analysts have shared their evaluations of 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.44, a high estimate of $18.00, and a low estimate of $6.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.0%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750791626_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive 10x Genomics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$6.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 10x Genomics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 10x Genomics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of 10x Genomics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of 10x Genomics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TXG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on 10x Genomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About 10x Genomics</h2>
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
<h3>A Deep Dive into 10x Genomics's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, 10x Genomics showcased positive performance, achieving a revenue growth rate of 9.84% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: 10x Genomics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -22.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): 10x Genomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.85%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.77%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: 10x Genomics's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

iShares Fallen Angels USD Bond ETF

Notizie

Ultime notizie per iShares Fallen Angels USD Bond ETF (NASDAQ:FALN)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO